Annexon, Inc. (ANNX) Stock
6 of the hedge funds AlphaScala tracks reported ANNX in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Point72's at $7.90M. Company insiders reported 1 open-market buy and 0 sales on SEC Form 4 in the 90 days to Oct 21, 2026.
Which hedge funds own ANNX?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Point72 Steve Cohen | 1.38M | $7.90M | -26% |
| Millennium Management Israel Englander | 1.18M | $6.77M | -4% |
| Citadel Ken Griffin | 597K | $3.41M | -1% |
| Renaissance Technologies Jim Simons (founder) | 459K | $2.62M | -16% |
| D.E. Shaw David Shaw | 265K | $1.51M | -62% |
| Marshall Wace | 211K | $1.20M | -76% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Annexon, Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Sep 24, 26 | Love Douglas | PRESIDENT AND CEO | BUY | 26.1K | $100K |
SEC Form 4 filings as of Oct 21, 2026
See cluster-buy signals across all tickers →ANNX price chart
Powered by TradingViewWhat does Annexon, Inc. do?
Annexon, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing therapeutics for autoimmune, neurodegenerative, and ophthalmic diseases. The company advances a pipeline of product candidates designed to target the classical complement pathway, a key component of the immune system implicated in these debilitating conditions. Its lead programs address unmet needs in areas such as Guillain-Barré syndrome, Huntington's disease, and geographic atrophy associated with age-related macular degeneration. Annexon, Inc. emphasizes innovative monoclonal antibodies that modulate complement activity to halt disease progression and preserve neurological and retinal function. Operating within the biotechnology industry of the healthcare sector, the company conducts clinical trials to evaluate the safety, efficacy, and potential of its therapies in patient populations. Founded in 2011 and headquartered in Brisbane, California, Annexon, Inc. plays a role in advancing treatments for complement-mediated disorders through rigorous scientific research and development efforts.